49 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 49 of 49 clinical reviews.
A clinical and insurance guide explaining Blue Cross Blue Shield Federated coverage, prior authorization, formulary tier, step therapy, and appeal strategies for oral micronized progesterone (Prometrium).
Find out whether Cigna covers oral micronized progesterone (Prometrium), what formulary tier it falls on, prior authorization requirements, step therapy rules, and how to appeal a denial.
A guide to Humana's coverage rules, prior authorization criteria, formulary tiers, step-therapy requirements, and appeal pathways for oral micronized progesterone (Prometrium).
Kaiser Permanente coverage details for oral micronized progesterone (Prometrium), including formulary tier, prior authorization requirements, step therapy, appeal options, and cost-saving alternatives.
Medicare Advantage plans generally cover oral micronized progesterone (Prometrium) for endometrial protection during HRT. Learn about formulary tiers, prior authorization, step therapy, and how to appeal a denial.
State Medicaid coverage for oral micronized progesterone varies widely. Learn formulary tiers, prior authorization rules, step therapy requirements, and how to appeal a denial.
A complete guide to TRICARE coverage, formulary tier, prior authorization criteria, step therapy requirements, and appeal strategies for oral micronized progesterone (Prometrium) used in hormone therapy.
A clinical and insurance guide to UnitedHealthcare coverage, prior authorization, step therapy, formulary tier, and appeal strategies for oral micronized progesterone (Prometrium).
50 mg is below standard dosing. Menopause HRT typically uses 100 mg nightly continuous or 200 mg for 12 days cyclic per the PEPI Trial protocol.
What to check after missing oral micronized progesterone, why Prometrium, Utrogestan, and combined capsules cannot share one cutoff, and which regimen details matter.
What the FDA label and clinical evidence actually support for oral micronized progesterone (Prometrium) dosing in adults 30 to 49, including cyclic versus continuous regimens, off-label uses, monitoring, and when to escalate care.
Evidence-based safety profile of oral micronized progesterone (Prometrium) for young adults aged 18 to 29, covering side effects, contraindications, fertility considerations, and clinical monitoring.
Evidence-based guide to every clinically significant drug-drug interaction with oral micronized progesterone (Prometrium), including CYP3A4 inhibitors, inducers, CNS depressants, and hormone therapy combinations.
A physician-level guide to oral micronized progesterone (Prometrium) pharmacokinetics, absorption variability, and dosing strategy after Roux-en-Y gastric bypass, sleeve gastrectomy, and other bariatric procedures. Covers the PEPI Trial evidence base, post-bariatric malabsorption data, and when to switch routes.
A clinician-level review of how oral micronized progesterone (Prometrium) affects cognitive function, memory, mood, and neuroprotection, with primary-literature citations and dosing guidance.
A clinician-level review of how oral micronized progesterone (Prometrium) affects bone mineral density, the mechanisms behind it, key trial data, and practical prescribing guidance for HRT patients.
A clinician-level review of oral micronized progesterone (Prometrium) cardiovascular effects, covering lipid profiles, arterial function, coronary risk, and how it compares to synthetic progestins in long-term hormone therapy.
A detailed cost and clinical comparison of oral micronized progesterone (Prometrium) against medroxyprogesterone acetate, norethindrone acetate, levonorgestrel IUD, and compounded progesterone for HRT endometrial protection.
A guide to oral micronized progesterone (Prometrium) dosing for adults aged 50 to 64, covering continuous and cyclic regimens, endometrial protection, side-effect management, and guideline recommendations.
Evidence-based guide to adjusting oral micronized progesterone (Prometrium) dosing in patients with liver disease, including pharmacokinetic changes, alternative routes, and clinical monitoring strategies.
A clinician-oriented guide to oral micronized progesterone (Prometrium) dosing, pharmacokinetics, and monitoring considerations in patients with chronic kidney disease or renal impairment, with an evidence-boundary review and a dosing decision framework.
A guide to oral micronized progesterone (Prometrium) dosing in adults 65 and older, covering evidence-based doses, fall risk, drug interactions, renal considerations, and deprescribing strategies.
Evidence-based monitoring guide for oral micronized progesterone (Prometrium) in patients aged 65 and older, covering labs, safety checks, deprescribing triggers, and clinical decision points.
Evidence-based safety review of oral micronized progesterone (Prometrium) in geriatric patients aged 65 and older, covering dosing, risks, monitoring, drug interactions, and deprescribing.
Evidence-based review of oral micronized progesterone (Prometrium) safety during pregnancy and breastfeeding, including FDA labeling, clinical trial data from PROMISE and PRISM, and lactation compatibility.
Complete guide to monitoring oral micronized progesterone (Prometrium) in adults aged 30-49. Covers baseline labs, follow-up schedules, serum progesterone levels, endometrial surveillance, lipid panels, and liver function testing.
Evidence-based monitoring guide for oral micronized progesterone (Prometrium) in adults aged 50 to 64 on HRT, covering labs, imaging, safety checks, and follow-up intervals.
Evidence-based monitoring schedule for oral micronized progesterone (Prometrium) on HRT, including recommended labs, imaging, endometrial surveillance, and follow-up intervals.
A clinical review of oral micronized progesterone (Prometrium) off-label applications, from sleep and neuroprotection to preterm birth prevention, graded by strength of evidence.
A clinical review of the Prometrium patent history, generic progesterone availability, and what prescribers need to know about current formulation options and upcoming developments.
How CYP3A4, CYP2C19, GABRA variants, and PGR polymorphisms alter oral micronized progesterone (Prometrium) metabolism, sedation risk, and endometrial protection. MD-level pharmacogenomics review with PubMed-cited evidence.
A physician-level review of oral micronized progesterone (Prometrium) pharmacokinetics, covering absorption variability, peanut-oil matrix effects, hepatic metabolism, active neurosteroid metabolites, and clinical dosing implications backed by PubMed-cited evidence.
A clinical review of real-world evidence from registries, observational cohorts, and RWE databases on oral micronized progesterone (Prometrium) for endometrial protection in hormone therapy.
A physician-level review of oral micronized progesterone (Prometrium) regulatory approvals, indications, and prescribing frameworks across the US, EU, Canada, and UK.
A clinical review of oral micronized progesterone (Prometrium) safety in adults aged 30 to 49, covering side effects, cardiovascular risk, breast safety, drug interactions, and monitoring guidelines.
A guide to oral micronized progesterone (Prometrium) safety for adults ages 50 to 64, covering trial evidence, dosing, drug interactions, cardiovascular risk, and when to use alternatives.
A clinical review of oral micronized progesterone (Prometrium) safety signals, FDA labeling changes, black box warnings, and risk data from PEPI, WHI, and E3N studies.
A clinician-level review of how oral micronized progesterone (Prometrium) reshapes sleep architecture, with primary-literature citations, dosing guidance, and practical prescribing considerations for HRT patients.
A physician-level guide to adjusting oral micronized progesterone (Prometrium) dosing during travel, transmeridian flights, and timezone shifts, with primary-literature citations and a clinical decision framework.
Evidence-based dosing guide for oral micronized progesterone (Prometrium) in young adults aged 18, 29, covering cyclic and continuous regimens, fertility considerations, and clinical monitoring.
Does oral micronized progesterone (Prometrium) increase appetite or trigger cravings? A clinician-level review of the evidence, mechanisms, and management strategies for women on HRT.
A guide to how food, alcohol, herbs, and supplements affect oral micronized progesterone (Prometrium) absorption, metabolism, and safety, with dosing guidance and primary-source citations.
A clinical review of upcoming oral micronized progesterone formulations, novel delivery systems, and pipeline developments including TX-001HR, segesterone acetate combinations, and extended-release progesterone technologies.
A clinical history of oral micronized progesterone (Prometrium), from early extraction failures through micronization technology, the PEPI trial, and modern HRT guidelines.
A clinical deep-dive into oral micronized progesterone (Prometrium) manufacturing processes, supply chain vulnerabilities, FDA shortage records, and what prescribers and patients should know about sourcing this essential HRT medication.
Oral micronized progesterone binds PR-A/PR-B to trigger secretory changes, plus how its allopregnanolone metabolite acts on GABA-A receptors for sedation.
Plan stopping oral progesterone around your estrogen treatment, prescribed cyclic breaks, bleeding changes and follow-up needs.
How to store oral progesterone, read Prometrium temperature limits and expiry dates, and handle heat, moisture or damaged capsules.
Evidence-based guide to switching between oral micronized progesterone (Prometrium) and other progestogens in hormone therapy, including dosing protocols, washout periods, and endometrial safety data.